前收市價 | 80.70 |
開市 | 無 |
買盤 | 101.00 |
賣出價 | 110.00 |
拍板 | 460.00 |
到期日 | 2026-06-18 |
今日波幅 | 80.70 - 80.70 |
合同範圍 | 無 |
成交量 | |
未平倉合約 | 25 |
Under her predecessor, Vertex revolutionized the treatment of cystic fibrosis. Kewalramani’s job is to maintain that franchise while guiding Vertex to its next big thing. There are plenty of options: Vertex is developing a pain medicine called suzetrigine that could satisfy enormous demand for a nonopioid pain reliever, and a stem-cell-derived therapy called VX-880 that the company hopes will be a cure for Type 1 diabetes, among many programs.
Lilly is a good pick...but this one is better.
We recently published a list Analyst Recommends 10 Best Stocks to Diversify Your Portfolio Away from Mega-Cap Tech and AI Stocks. Since Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) ranks 7th on the list, it deserves a deeper look. Venu Krishna, Head of U.S. Equity Strategy & Global Equity Linked Strategies at Barclays, recently shared a basket of stocks […]